RxDoctor Payments Data

Tahereh Jamshidi

Rheumatology · Washington, DCNPI 1225201916

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (35.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Aurinia Pharma U.S., Inc. at 29.0% of the total. Reporting peaked in 2021 at $3,088 and has fallen 96.2% since, to $119 in 2025.

$9,918in general payments, 2019–2025

Across 112 payments — averaging $88.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$3K
  • Sobi, Inc$3K
  • Amgen$2K
  • Mallinckrodt Hospital Products Inc.$775
  • Novartis$325
  • AstraZeneca$256
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$3,09831%
  • Speaking & faculty fees$3,52035%
  • Food & beverage$3,30133%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,918 in reported general payments places this provider in the 70th percentile of 41 rheumatology providers in District of Columbia.

See all rheumatology providers in District of Columbia

Other rheumatology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →